Overall, GLP‐1 RAs in T2D provide meaningful improvements in glycaemic control regardless of age to allow recipients to achieve the glycaemia‐focused treatment goals (Nauck et al., 2020). This evidence concerns the gene GCG and type 2 diabetes mellitus.